Research programme: anti-fungal drugs - REVOLUTION Medicines
Latest Information Update: 28 Mar 2019
At a glance
- Originator University of Illinois at Urbana-Champaign
- Developer REVOLUTION Medicines
- Class Small molecules
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for research development in Mycoses in USA
- 04 Feb 2015 REVOLUTION Medicines entered into an exclusive license agreement with the University of Illinois Urbana-Champaign, for the lead anti-fungal programme and the building block synthesis platform technology
- 04 Feb 2015 Early research in Mycoses in USA (unspecified route)